pembrolizumab,enfortumab vedotin
seagen,astellas,merck,beigene,eisai,novartis
['keytruda', 'padcev', 'bladder']
esmo congress 2022 features padcev-keytruda combo data in bladder cancer and liver cancer data from pd-1 inhibitors. 
Tweets from the Fierce Life Sciences editorial team